1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Adenocarcinoma – Pipeline Review, H1 2013

Adenocarcinoma – Pipeline Review, H1 2013

  • February 2013
  • -
  • Global Markets Direct
  • -
  • 172 pages

Adenocarcinoma – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Adenocarcinoma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Adenocarcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Adenocarcinoma. Adenocarcinoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Adenocarcinoma.
- A review of the Adenocarcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Adenocarcinoma pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Adenocarcinoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Adenocarcinoma pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Adenocarcinoma - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Adenocarcinoma Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Adenocarcinoma 9
Adenocarcinoma Therapeutics under Development by Companies 11
Adenocarcinoma Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Pre-Clinical Stage Products 21
Comparative Analysis 21
Adenocarcinoma Therapeutics - Products under Development by Companies 22
Adenocarcinoma Therapeutics - Products under Investigation by Universities/Institutes 24
Companies Involved in Adenocarcinoma Therapeutics Development 27
Amgen Inc. 27
Sanofi-Aventis 28
Gilead Sciences, Inc. 29
Delcath Systems, Inc. 30
Novartis AG 31
Astellas Pharma Inc. 32
Aduro BioTech 33
Merck KGaA 34
Celldex Therapeutics, Inc. 35
Lorus Therapeutics Inc 36
Peregrine Pharmaceuticals, Inc. 37
Threshold Pharmaceuticals, Inc. 38
GANYMED Pharmaceuticals AG 39
MacroGenics, Inc. 40
BioCancell Therapeutics, Inc. 41
Kinex Pharmaceuticals, LLC 42
Eleison Pharmaceuticals, Inc. 43
Laboratorio Elea S.A.C.I.F. and A 44
Adenocarcinoma - Therapeutics Assessment 45
Assessment by Monotherapy Products 45
Assessment by Combination Products 46
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 52
CDX-1127 - Drug Profile 52
ASG-5-ME - Drug Profile 53
LOR-1284 - Drug Profile 55
pimasertib - Drug Profile 56
glufosfamide - Drug Profile 59
TH-302 - Drug Profile 61
bavituximab - Drug Profile 63
MT-111 - Drug Profile 68
IMAB-362 - Drug Profile 69
pioglitazone hydrochloride - Drug Profile 71
zoledronic acid - Drug Profile 72
bevacizumab + [docetaxel] + [irinotecan hydrochloride hydrochloride] + [oxaliplatin] - Drug Profile 74
everolimus + [paclitaxel] + [carboplatin] - Drug Profile 75
bortezomib - Drug Profile 77
Docetaxel + Oxaliplatin + Capecitabine + Fluorouracil + Radiation Therapy - Drug Profile 79
DC-Tn-MUC1 Vaccine - Drug Profile 81
bevacizumab + [cetuximab] + [fluorouracil] + [irinotecan hydrochloride] + [leucovorin calcium] + [oxaliplatin] - Drug Profile 82
Melphalan + Chemosaturation Therapy - Drug Profile 84
irofulven - Drug Profile 86
capecitabine + oxaliplatin - Drug Profile 87
TH-302 + [gemcitabine hydrochloride] - Drug Profile 88
Docetaxel + Androgen Deprivation + Proton Therapy - Drug Profile 90
cetuximab + [fluorouracil] + [gemcitabine] + Radiation Therapy - Drug Profile 92
artesunate - Drug Profile 94
bevacizumab + [cisplatin] + [docetaxel] + [fluorouracil] + leucovorin - Drug Profile 95
cetuximab + [gemcitabine] + Radiation Therapy - Drug Profile 96
bevacizumab + capecitabine + [carboplatin] - Drug Profile 97
bevacizumab + [paclitaxel] + [topotecan hydrochloride] - Drug Profile 98
bevacizumab + [erlotinib hydrochloride] + [gemcitabine hydrochloride] - Drug Profile 99
Cancer Macrobeads - Drug Profile 100
bevacizumab + erlotinib hydrochloride - Drug Profile 101
vvDD-CDSR - Drug Profile 103
epirubicin hydrochloride + [docetaxel] - Drug Profile 104
Modified CEA (CAP1-6D) Peptide - Drug Profile 105
bevacizumab + [capecitabine] + [oxaliplatin] - Drug Profile 106
Glypican-3 Peptide Vaccine - Drug Profile 107
Docetaxel + S-1 - Drug Profile 108
Glypican-3 Peptide Vaccine - Drug Profile 109
cabazitaxel - Drug Profile 111
GS-6624 - Drug Profile 112
Taxotere + Leuprolide + Radiation Therapy - Drug Profile 114
bevacizumab + [gemcitabine hydrochloride] + Radiation Therapy - Drug Profile 116
Taxotere + Oblimersen - Drug Profile 117
bevacizumab + [cisplatin] + Radiation Therapy - Drug Profile 118
BKM-120 + [irinotecan hydrochloride] - Drug Profile 119
mitoxantrone hydrochloride + [docetaxel] - Drug Profile 120
erlotinib hydrochloride + [bevacizumab] + [capecitabine] + [fluorouracil] + [leucovorin calcium] + [oxaliplatin] - Drug Profile 121
bevacizumab + cetuximab + [erlotinib hydrochloride] + [gemcitabine hydrochloride] - Drug Profile 123
altretamine + melphalan - Drug Profile 125
CIGB-300 - Drug Profile 126
HM30181A + Paclitaxel - Drug Profile 127
MGARG-2 - Drug Profile 128
GVAX Pancreas + CRS-207 + [cyclophosphamide] - Drug Profile 130
GnRHm1-TT - Drug Profile 132
BC-819 + [gemcitabine] - Drug Profile 134
PEI/DNA + Gemzar - Drug Profile 136
Poly-ICLC + Dendritic Cells - Drug Profile 138
Silymarin - Drug Profile 139
MCT-1 Inhibitors - Drug Profile 140
Adenocarcinoma Therapeutics - Drug Profile Updates 142
Adenocarcinoma Therapeutics - Discontinued Products 157
Adenocarcinoma Therapeutics - Dormant Products 159
Adenocarcinoma - Product Development Milestones 165
Featured News and Press Releases 165
Appendix 167
Methodology 167
Coverage 167
Secondary Research 167
Primary Research 167
Expert Panel Validation 167
Contact Us 168
Disclaimer 168



List of Tables

Number of Products Under Development for Adenocarcinoma, H1 2013 13
Products under Development for Adenocarcinoma - Comparative Analysis, H1 2013 14
Number of Products under Development by Companies, H1 2013 16
Number of Products under Development by Companies, H1 2013 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H1 2013 19
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 20
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 21
Comparative Analysis by Late Stage Development, H1 2013 22
Comparative Analysis by Mid Clinical Stage Development, H1 2013 23
Comparative Analysis by Early Clinical Stage Development, H1 2013 24
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 25
Products under Development by Companies, H1 2013 26
Products under Development by Companies, H1 2013 (Contd..1) 27
Products under Investigation by Universities/Institutes, H1 2013 28
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 29
Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 30
Amgen Inc., H1 2013 31
Sanofi-Aventis, H1 2013 32
Gilead Sciences, Inc., H1 2013 33
Delcath Systems, Inc., H1 2013 34
Novartis AG, H1 2013 35
Astellas Pharma Inc., H1 2013 36
Aduro BioTech, H1 2013 37
Merck KGaA, H1 2013 38
Celldex Therapeutics, Inc., H1 2013 39
Lorus Therapeutics Inc, H1 2013 40
Peregrine Pharmaceuticals, Inc., H1 2013 41
Threshold Pharmaceuticals, Inc., H1 2013 42
GANYMED Pharmaceuticals AG, H1 2013 43
MacroGenics, Inc., H1 2013 44
BioCancell Therapeutics, Inc., H1 2013 45
Kinex Pharmaceuticals, LLC, H1 2013 46
Eleison Pharmaceuticals, Inc., H1 2013 47
Laboratorio Elea S.A.C.I.F. and A, H1 2013 48
Assessment by Monotherapy Products, H1 2013 49
Assessment by Combination Products, H1 2013 50
Assessment by Stage and Route of Administration, H1 2013 52
Assessment by Stage and Molecule Type, H1 2013 55
Adenocarcinoma Therapeutics - Drug Profile Updates 146
Adenocarcinoma Therapeutics - Discontinued Products 161
Adenocarcinoma Therapeutics - Discontinued Products (Contd..1) 162
Adenocarcinoma Therapeutics - Dormant Products 163
Adenocarcinoma Therapeutics - Dormant Products (Contd..1) 164
Adenocarcinoma Therapeutics - Dormant Products (Contd..2) 165
Adenocarcinoma Therapeutics - Dormant Products (Contd..3) 166
Adenocarcinoma Therapeutics - Dormant Products (Contd..4) 167
Adenocarcinoma Therapeutics - Dormant Products (Contd..5) 168



List of Figures

Number of Products under Development for Adenocarcinoma, H1 2013 13
Products under Development for Adenocarcinoma - Comparative Analysis, H1 2013 14
Products under Development by Companies, H1 2013 15
Products under Investigation by Universities/Institutes, H1 2013 18
Late Stage Products, H1 2013 22
Mid Clinical Stage Products, H1 2013 23
Early Clinical Stage Products, H1 2013 24
Pre-Clinical Stage Products, H1 2013 25
Assessment by Monotherapy Products, H1 2013 49
Assessment by Combination Products, H1 2013 50
Assessment by Route of Administration, H1 2013 51
Assessment by Stage and Route of Administration, H1 2013 52
Assessment by Molecule Type, H1 2013 53
Assessment by Stage and Molecule Type, H1 2013 54

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Opioid Market in the US

  • December 2016
    14 pages
  • Opioid  

  • United States  

View report >

Therapy Market in Denmark - Forecast

  • December 2016
    12 pages
  • Therapy  

  • Denmark  

View report >

Related Market Segments :

Therapy
Chemotherapy
Targeted Therapy

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.